Drug Utilization Review (DUR) Meeting Minutes
September 8, 2008

Members Present: Patricia Churchill, Cheryl Huber, Norman Byers, Carrie Sorenson, Greg Pfister, Bob Treitline, Kim Krohn, Jeffrey Hostetter, John Savageau, Scott Setzepfandt, and Leeann Ness, Carlotta McCleary and Todd Twogood.
Medicaid Pharmacy Department: Brendan Joyce, Gary Betting
HID Staff Present: Candace Rieth

Chair, C. Sorenson, called the meeting to order at 1:05pm. C. Sorenson asked for a motion to approve the minutes from the June meeting. N. Byers moved that the minutes be approved and C. Huber seconded the motion. Chair, C. Sorenson, called for a voice vote to approve the minutes. The motion passed.

Budget Update
B. Joyce had no new information to present regarding the budget.

Summary of Board Recommendations to Legislative Counsel
Previous board recommendations on HIV/AIDS, Oncology, ADHD, Antidepressants, and Antipsychotics were reviewed. C. Huber mentioned that the summary did not include the decision by the board to not make any recommendations regarding anticonvulsants. B. Treitline made a motion that the Summary of Board Recommendations should be modified based on the past meeting's minutes. G. Pfister seconded the motion. Chair, C. Sorenson, called for a voice vote and the motion passed. B. Joyce stated that the completed recommendations will be sent to the legislative council before October 1st to meet the requirements of the law.

Second Review of Chantix
At the June meeting, J. Hostetter made a motion requesting the Department formulate a smoking cessation plan that would cover all smoking cessation products for recipients enrolled in the ND Tobacco Quitline. B. Joyce presented the smoking cessation plan to the DUR Board. He said it did not include all smoking cessation products as the nicotine inhaler and nicotine nasal spray are not recommended by the Health Department's Quitline. Each smoking cessation product will be covered for a 90 day supply over a 2 year period of time. Chantix will be covered for a 6 month supply over a 2 year period of time. It was recommended by the Board that patients stop smoking during the first three months of therapy with Chantix. Patients will be contacted by the Quitline once a month. After the first three months of Chantix therapy, the Quitline will verify that patients have stopped smoking and a prior authorization will be required for the next three months of therapy. T. Twogood made a motion to remove the age limit from the guidelines. J. Savageau seconded the motion. Chair, C. Sorenson, called for a voice vote to amend the age on the presented plan as well as implement the smoking cessation program as amended. Both the amendment to the motion and the amended motion passed. B. Joyce informed the Board that a State Plan Amendment (SPA) will need to be filed with CMS to gain approval to cover smoking cessation products. Programming changes will also need to be made. It is hoped that the changes will be in place in October which would then allow the products to be covered in the fashion approved by the board.

Second Review of Soma 250
At the June meeting, Board members made two motions regarding carisoprodol. The first was a motion to place Soma 250 on prior authorization. The second motion recommended that all new prescriptions for carisoprodol be limited to 3 weeks supply with one refill per year. Board members suggested sending provider letters for patients taking carisoprodol on a chronic basis offering the option of grandfathering a patient or weaning a patient over a 6 month period of time. Chronic was defined as greater than 5 scripts per year of carisoprodol. B. Treitline amended the motion to include a prior authorization on carisoprodol and an option for grandfathering patients

currently taking carisoprodol. J. Savageau seconded the motion. Chair, C. Sorenson, called for a voice vote to approve the original motion with the amendment. The motion passed.

Review of Triptans
B. Joyce reviewed triptan utilization with Board members. J. Kelloway, representing GSK, spoke on behalf of Treximet. T. Hartman, representing Pfizer, spoke on behalf of Relpax. N. Byers made a motion to make Imitrex first line for North Dakota Medicaid recipients. G. Pfister seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

Review of Intranasal Corticosteroids
B. Joyce reviewed intranasal corticosteroid utilization with Board members. M. Cardenas, representing GSK, spoke on behalf of Veramyst. K. Hesterman, representing Schering-Plough, spoke on behalf of Nasonex. After much discussion, the topic of intranasal corticosteroids was tabled.

Review of Vusion
B. Joyce reviewed Vusion utilization with Board members. There was no public comment. T. Twogood made a motion to prior authorize Vusion. J. Hostetter seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

Yearly PA Review
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Growth Hormone/IGF-1 products, ARBs/Renin Inhibitors, Brand Medically Necessary, Amrix and Xenical were reviewed. S. Setzepfandt, representing Roche, recused himself as a Board member and spoke on behalf of Xenical suggesting the BMI criteria be changed to 30. Dana Myer, representing Novartis (Sandoz), spoke on behalf of Omnitrope. No changes were made to the forms and criteria for these agents.

Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. J. Savageau moved to approve the new criteria and C. Huber seconded the motion. Chair, C. Sorenson called for a voice vote. The motion passed.

The next DUR board meeting will be held December 1, 2008. C. Huber made a motion to adjourn the meeting and J. Hostetter seconded. Chair C. Sorenson adjourned the meeting at 3:35 pm.